WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue results for the quarter ended September 30, 2006. The Company expects to record total third quarter revenues of slightly more than $11 million, with approximately $4 million from ANTARA(R) 130 mg (fenofibrate) capsules and approximately $4 million in revenues related to FACTIVE(R)(gemifloxacin mesylate) tablets. The Company plans to announce complete financial results and host a conference call with investors on November 9, 2006.
